170 related articles for article (PubMed ID: 25252705)
1. Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey.
Spina A; Eramova I; Lazarus JV
BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S15. PubMed ID: 25252705
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B and C surveillance and screening programmes in the non-EU/EEA Member States of the WHO European Region: survey findings from 10 countries, 2012.
Mozalevskis A; Eramova I; Safreed-Harmon K; Lazarus JV
Euro Surveill; 2016 Jun; 21(22):. PubMed ID: 27277421
[TBL] [Abstract][Full Text] [Related]
3. Strengthening hepatitis B and C surveillance in Europe: results from the two global hepatitis policy surveys (2013 and 2014).
Lazarus JV; Mozalevskis A; Safreed-Harmon K; Eramova I
Hepatol Med Policy; 2016; 1():3. PubMed ID: 30288307
[TBL] [Abstract][Full Text] [Related]
4. Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries.
Maticic M; Videcnik Zorman J; Gregorcic S; Schatz E; Lazarus JV
BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S14. PubMed ID: 25252635
[TBL] [Abstract][Full Text] [Related]
5. Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017.
Lazarus JV; Stumo SR; Harris M; Hendrickx G; Hetherington KL; Maticic M; Jauffret-Roustide M; Tallada J; Simojoki K; Reic T; Safreed-Harmon K;
J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25052. PubMed ID: 29633562
[TBL] [Abstract][Full Text] [Related]
6. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.
Lazarus JV; Shete PB; Eramova I; Merkinaite S; Matic S
Int J Drug Policy; 2007 Oct; 18(5):426-32. PubMed ID: 17854732
[TBL] [Abstract][Full Text] [Related]
7. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.
Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012021. PubMed ID: 28922449
[TBL] [Abstract][Full Text] [Related]
8. National policies for delivering tuberculosis, HIV and hepatitis B and C virus infection services for refugees and migrants among Member States of the WHO European Region.
Baggaley RF; Nazareth J; Divall P; Pan D; Martin CA; Volik M; Seguy NS; Yedilbayev A; Reinap M; Vovc E; Mozalevskis A; Dadu A; Waagensen E; Kruja K; Sy TR; Nellums L; Pareek M
J Travel Med; 2023 Feb; 30(1):. PubMed ID: 36426801
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region.
Lazarus JV; Sperle I; Maticic M; Wiessing L
BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S16. PubMed ID: 25252742
[TBL] [Abstract][Full Text] [Related]
10. WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs.
Walsh N; Verster A; Rodolph M; Akl EA
Int J Drug Policy; 2014 May; 25(3):363-71. PubMed ID: 24561223
[TBL] [Abstract][Full Text] [Related]
11. Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries.
Maticic M; Zorman JV; Gregorcic S; Schatz E; Lazarus JV
Harm Reduct J; 2019 May; 16(1):32. PubMed ID: 31072401
[TBL] [Abstract][Full Text] [Related]
12. Monitoring response to hepatitis B and C in EU/EEA: testing policies, availability of data on care cascade and chronic viral hepatitis-related mortality - results from two surveys (2016).
Aspinall EJ; Hutchinson SJ; Goldberg DJ; Valerio H; Mozalevskis A; Noori T; Duffell E; Tavoschi L
HIV Med; 2018 Feb; 19 Suppl 1():11-15. PubMed ID: 29488708
[TBL] [Abstract][Full Text] [Related]
13. Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study.
Safreed-Harmon K; Hetherington KL; Aleman S; Alho H; Dalgard O; Frisch T; Gottfredsson M; Weis N; Lazarus JV;
PLoS One; 2018; 13(1):e0190146. PubMed ID: 29381697
[TBL] [Abstract][Full Text] [Related]
14. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
[TBL] [Abstract][Full Text] [Related]
15. Global progress on the elimination of viral hepatitis as a major public health threat: An analysis of WHO Member State responses 2017.
Smith S; Harmanci H; Hutin Y; Hess S; Bulterys M; Peck R; Rewari B; Mozalevskis A; Shibeshi M; Mumba M; Le LV; Ishikawa N; Nolna D; Sereno L; Gore C; Goldberg DJ; Hutchinson S
JHEP Rep; 2019 Aug; 1(2):81-89. PubMed ID: 32039355
[TBL] [Abstract][Full Text] [Related]
16. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*.
Hatzakis A; Wait S; Bruix J; Buti M; Carballo M; Cavaleri M; Colombo M; Delarocque-Astagneau E; Dusheiko G; Esmat G; Esteban R; Goldberg D; Gore C; Lok AS; Manns M; Marcellin P; Papatheodoridis G; Peterle A; Prati D; Piorkowsky N; Rizzetto M; Roudot-Thoraval F; Soriano V; Thomas HC; Thursz M; Valla D; van Damme P; Veldhuijzen IK; Wedemeyer H; Wiessing L; Zanetti AR; Janssen HL
J Viral Hepat; 2011 Sep; 18 Suppl 1():1-16. PubMed ID: 21824223
[TBL] [Abstract][Full Text] [Related]
17. Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries.
Ishizaki A; Bouscaillou J; Luhmann N; Liu S; Chua R; Walsh N; Hess S; Ivanova E; Roberts T; Easterbrook P
BMC Infect Dis; 2017 Nov; 17(Suppl 1):696. PubMed ID: 29143609
[TBL] [Abstract][Full Text] [Related]
18. Who: four ways to reduce hepatitis infections in people who inject drugs.
Cent Eur J Public Health; 2012 Sep; 20(3):207. PubMed ID: 23285521
[No Abstract] [Full Text] [Related]
19. Prevalence of injecting drug use and HIV, hepatitis B, and hepatitis C in people who inject drugs in the Eastern Mediterranean region: a systematic review and meta-analysis.
Aghaei AM; Gholami J; Sangchooli A; Rostam-Abadi Y; Olamazadeh S; Ardeshir M; Baheshmat S; Shadloo B; Taj M; Saeed K; Rahimi-Movaghar A
Lancet Glob Health; 2023 Aug; 11(8):e1225-e1237. PubMed ID: 37474230
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.
Day E; Hellard M; Treloar C; Bruneau J; Martin NK; Øvrehus A; Dalgard O; Lloyd A; Dillon J; Hickman M; Byrne J; Litwin A; Maticic M; Bruggmann P; Midgard H; Norton B; Trooskin S; Lazarus JV; Grebely J;
Liver Int; 2019 Jan; 39(1):20-30. PubMed ID: 30157316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
